Llwytho...
Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
Alzheimer’s disease (AD) is characterized by the presence of amyloid plaques composed mainly of amyloid-β (Aβ) protein. Overproduction or slow clearance of Aβ initiates a cascade of pathologic events that may lead to formation of neurofibrillary tangles, neuronal cell death, and dementia. Although i...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Immunotargets Ther |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2013
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918231/ https://ncbi.nlm.nih.gov/pubmed/27471697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S40131 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|